About Us

The Vermont Center for Immunology and Infectious Diseases (VCIID) was initiated at the University of Vermont to create a multidisciplinary group of scientists and clinicians undertaking collaborative research in microbial pathogenesis and the immune response to infections. The ultimate goal is that our collective findings will translate into new strategies for the detection, prevention, and treatment of infectious diseases. We are also mindful that some of our research themes (e.g. inflammation) have clear relevance to other diseases, such as cancer, autoimmunity, and atherogenesis.

The Center currently includes approximately twenty-three UVM faculty in eight departments and three colleges. There is also a robust collaboration with the Trudeau Institute in nearby Saranac Lake, NY, manifested by a joint P01 Program Project Grant and T32 Training Grant. Over the next few years there will be a continued expansion through the recruitment of new faculty to the Center. An active seminar series brings to campus outstanding international investigators in immunology and microbiology. The Center also supports core facilities in microarray, bioinformatics, proteomics, and flow cytometry.

A research training program in Immunology and Infectious Diseases exists with opportunities for undergraduate and graduate students and postdoctoral fellows. This is supported by funds from both the COBRE and T32 Training Grant awards.

Clinical Trials for Infectious Diseases are conducted with the Division of Infectious Diseases, and for autoimmune and rheumatic diseases with the Division of Rheumatology and Clinical Immunology.

Collaborating Partners

Location

Our Burlington home is nestled between the shores of Lake Champlain and the vistas of the Green Mountains.

We are located on the University of Vermont campus, and adjacent to The University of Vermont Medical Center, fostering a culture of collaboration and partnership.

buddB_185x127

Message from the Director

The focus of the Vermont Center for Immunobiology and Infectious Diseases is the host response to infections.  During the first five years of Phase I COBRE funding from NIH we expanded from nine founding senior faculty to the current 23 faculty spanning eight departments in four colleges.  We published 213 original research papers and secured nearly $48 million in research dollars, not counting the COBRE funds.  In July 2011 we began Phase II of our COBRE grant from NIH for a second five years. The nearly $11 million will support new junior and senior faculty, an annual retreat, students, a robust seminar series of outside nationally recognized research, and pilot grants to foster new collaborations.

Ralph Budd, M.D.
Director, Professor of Medicine

thebestdefense_000

With a new multi-million dollar grant, a UVM group studies infectious agents that impact the health of millions of people worldwide.